Rakesh Popat

University College London Hospitals NHS Foundation Trust — United Kingdom

Medicine · Health Sciences

39h-index7.7kcitations388works4.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Multiple Myeloma Research and Treatments(308), Protein Degradation and Inhibitors(132), Peptidase Inhibition and Analysis(57), Monoclonal and Polyclonal Antibodies Research(45), CAR-T cell therapy research(45)

Publications387 total

Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial
The Lancet Oncology·2026· 1 citedOpen Access
Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study
Journal of Clinical Oncology·2025Open Access
Optimizing oncology drug development: systematic review of 22 years of myeloma randomized controlled trials
JNCI Journal of the National Cancer Institute·2025Open Access
Talquetamab, a GPRC5D×CD3 bispecific antibody, in combination with pomalidomide in patients with Relapsed/Refractory multiple myeloma: Updated safety and efficacy results from the Phase 1b monumental-2 study
Blood·2025Open Access
Real world efficacy and safety of elranatamab, a BCMA bispecific antibody for patients with relapsed and refractory multiple myeloma: An international myeloma working group immunotherapy database analysis
Blood·2025
Trial in progress: QUINTESSENTIAL-2—a phase 3 study of arlocabtagene autoleucel versus standard of care in adult patients with relapsed and refractory multiple myeloma (RRMM) exposed to lenalidomide
Blood·2025
Factors influencing patient treatment selection among bispecific antibodies for relapsed/refractory multiple myeloma (RRMM): A mixed methods study
Blood·2025
Double hit ultra-high risk myeloma treated with isatuximab, bortezomib, lenalidomide, dexamethasone and cyclophosphamide (Isa-VRDc) induction and isa-VRD consolidation: Initial results of the UK myeloma research alliance (UKMRA)  RADAR trial in newly diagnosed transplant eligible patients
Blood·2025
Initial phase 1b/2 study results with sonrotoclax (BGB-11417) in combination with carfilzomib and dexamethasone in patients with t(11;14)-positive relapsed/refractory multiple myeloma
Blood·2025Open Access
Quality-adjusted survival analysis of neurologic events with ciltacabtagene autoleucel (Cilta-cel) vs standard of care (SOC) in patients (Pts) with lenalidomide-refractory multiple myeloma (MM) who received 1–3 prior lines of therapy (LOT): Cartitude-4 trial population (Pop)
Blood·2025Open Access
Safety results from REALiTAL: A multi-country observational retrospective study of talquetamab in patients with relapsed/refractory multiple myeloma outside of clinical trials
Blood·2025Open Access
Cancer-selective targeting of the NF-κB pathway via GADD45β/MKK7 inhibition: Results from the phase I trial of the first-in-class inhibitor, DTP3, in patients with relapsed or refractory multiple myeloma
Blood·2025Open Access
CAR-T cells co-targeting BCMA and CD19 in RRMM: Results from the UKMRA Phase 1 MCARTY trial in relapsed refractory multiple myeloma
Blood·2025
Utility and sensitivity of wett-SA53 to measure dysgeusia associated with talquetamab, a GPRC5D×CD3 bispecific antibody, in Relapsed/Refractory multiple myeloma: Preliminary data from the talisman study
Blood·2025Open Access
Short survival with BCMA and GPRC5D dual antigen exposed relapsed myeloma- an international myeloma working group immunotherapy database analysis
Blood·2025Open Access
Can a patient questionnaire (VRAT) reduce the need for ocular examinations with less frequent belantamab mafodotin combined with bortezomib and dexamethasone? the ukmra prommise d trial
Blood·2025
Sequencing BCMA‐ and GPRC5D‐targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma Network
HemaSphere·2025· 1 citedOpen Access
Characterization and Management of Cytokine Release Syndrome From the <scp>MonumenTAL</scp> ‐1 Study of Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma
Cancer Medicine·2025· 1 citedOpen Access
The Role of Radiotherapy for Patients With Multiple Myeloma in the Modern Era: A Real World Single‐Centre Experience
eJHaem·2025Open Access
Current quality of life questionnaires are not relevant for assessing QOL issues in multiple myeloma patients in the era of modern therapies: results from a survey with myeloma patients and myeloma healthcare professionals
Frontiers in Oncology·2025Open Access
page 1 of 20Next →

Frequent Co-authors

Kwee Yong(15), Niels W.C.J. van de Donk(12), Ajay K. Nooka(11), Philippe Moreau(10), María‐Victoria Mateos(10), Albert Oriol(9), Sagar Lonial(9), Paul G. Richardson(9), Neil Rabin(8), Ajai Chari(7), Nizar J. Bahlis(7), Joaquín Martínez‐López(7), Suzanne Trudel(7), Ira Gupta(7), Joanna Opalinska(7), Adam D. Cohen(7), Ashraf Badros(6), Paula Rodríguez‐Otero(6), Simon J. Harrison(6), Heather Oakervee(6)